Synthetic Design Lab
United States
- San Francisco Bay Area
- 24/04/2025
- Unknown
- $20,000,000
A next-generation ADC company developing a novel SYNTHBODY therapeutic platform against a range of cancer types
- Industry Biotechnology Research
- Website https://www.syntheticdesignlab.com/
- LinkedIn https://www.linkedin.com/company/synthetic-design-lab-inc/
Related People
Daniel Chen, M.D. Ph.D.Founder
United States -
Burlingame, California
Author of The Cancer-Immunity Cycle (Immunity 2013) and the Cancer-Immune Set Point (Nature 2017) with Ira Mellman.
A pioneer in the field of Cancer Immunotherapy, emergence of PD-L1/PD-1 inhibitors and next generation therapies. Focused on the future of medicine and what's possible at the intersection between engineering, science and medicine.
Experienced drug developer (from pre-clinical through Phase I-IV), entrepreneur, executive- strong communicator and strategic leader with expertise in Oncology, Immunology, Large Molecule Engineering, Virology, Filings, Biomarkers and Building/Leading Organizations.
Valinor | $13,000,000 | (Dec 12, 2025)
Keeper | $4,000,000 | (Dec 12, 2025)
Cyphlens | $3,800,000 | (Dec 12, 2025)
OnCorps AI | $55,000,000 | (Dec 12, 2025)
conveyd | $3,345,837 | (Dec 12, 2025)
Ritten | $35,000,000 | (Dec 12, 2025)
Safebooks AI | $15,000,000 | (Dec 12, 2025)
Double (1) | $6,500,000 | (Dec 12, 2025)
Yonda | $15,000,000 | (Dec 12, 2025)
Medra | $52,000,000 | (Dec 12, 2025)
Cynch AI | $9,000,000 | (Dec 12, 2025)
Empromptu.ai | $2,000,000 | (Dec 11, 2025)